Cowen analyst Joseph Thome downgraded Y-mAbs Therapeutics to Market Perform from Outperform without a price target. The company announced a workforce reduction and a pipeline reprioritization following omburtamab’s December Complete Response Letter, Thome tells investors in a research note. The analyst says that while Y-mAbs’ SADA platform could yield viable candidates and partnership opportunities to augment the Danyelza opportunity, he awaits additional pipeline clarity.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on YMAB:
- Y-mAbs Therapeutics announces strategic objectives for FY23
- Y-mAbs Therapeutics announces restructuring plan, to reduce workforce by 35%
- Y-mAbs Announces Restructuring Plan and Provides Financial Outlook Following Complete Response Letter from FDA
- Y-mAbs Therapeutics enters distribution agreement with WEP Clinical
- The CHMP has Adopted a Negative Opinion for Omburtamab for the Treatment of CNS/LM Metastasis from Neuroblastoma in Europe
